The IL-1RN and IL-4 gene polymorphisms are potential genetic markers of susceptibility to bladder cancer: a case-control study

We investigated the relationship between the distribution of the IL-1RN, TNF-beta and IL-4 polymorphism and the clinical features of bladder cancer. A total of 100 patients with bladder carcinoma and 102 healthy control subjects were enrolled in the study. The IL-1RN, IL-4 and TNF-beta gene polymorphisms were identified by PCR restriction fragment length polymorphism-based analysis. Allelic frequencies were compared between patient and the controls. Tumor stage, histopathological grade, tumor size/number and smoking condition were evaluated with IL-1RN, IL-4 and TNF-beta gene polymorphisms. Allele distribution frequencies of IL-1RN and IL-4 gene polymorphisms were significantly different between patients and control groups. However, allele distribution of TNF-beta gene was not statistically significant. There was no difference in allele distribution of the three genes in both groups regarding stage, tumor size, number of tumors and smoking condition. Although allele distribution of IL-4 gene showed significant difference considering histopathological grades in both smoking and total patients group, allele distribution of IL-1RN and TNF-beta was not different. The present research suggests that the IL-1RN and IL-4 gene polymorphisms are potential genetic markers of susceptibility to bladder cancer. In the future, clinical improvements on diagnosis, treatment and prognosis of bladder carcinoma are expected owing to development of more sensitive and specific tests for genetic polymorphisms of cytokines that are effective on inflammation.

Yazar Bozdogan, S. T.
Erol, B.
Dursun, A.
Bozdogan, G.
Donmez, I.
Mungan, N. A.
Seydaoglu, G.
Yayın Türü Article
Tek Biçim Adres https://hdl.handle.net/20.500.12628/3597
Tek Biçim Adres 10.1007/s00345-014-1323-4
Konu Başlıkları Bladder carcinoma
Gene polymorphisms
IL-1RN
IL-4
TNF-beta
Koleksiyonlar Araştırma Çıktıları | WoS | Scopus | TR-Dizin | PubMed | SOBİAD
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu
Dergi Adı WORLD JOURNAL OF UROLOGY
Dergi Cilt Bilgisi 33
Dergi Sayısı 3
Sayfalar 389 - 395
Yayın Yılı 2015
Eser Adı
[dc.title]
The IL-1RN and IL-4 gene polymorphisms are potential genetic markers of susceptibility to bladder cancer: a case-control study
Yazar
[dc.contributor.author]
Bozdogan, S. T.
Yazar
[dc.contributor.author]
Erol, B.
Yazar
[dc.contributor.author]
Dursun, A.
Yazar
[dc.contributor.author]
Bozdogan, G.
Yazar
[dc.contributor.author]
Donmez, I.
Yazar
[dc.contributor.author]
Mungan, N. A.
Yazar
[dc.contributor.author]
Seydaoglu, G.
Yayın Yılı
[dc.date.issued]
2015
Yayıncı
[dc.publisher]
SPRINGER
Yayın Türü
[dc.type]
article
Özet
[dc.description.abstract]
We investigated the relationship between the distribution of the IL-1RN, TNF-beta and IL-4 polymorphism and the clinical features of bladder cancer. A total of 100 patients with bladder carcinoma and 102 healthy control subjects were enrolled in the study. The IL-1RN, IL-4 and TNF-beta gene polymorphisms were identified by PCR restriction fragment length polymorphism-based analysis. Allelic frequencies were compared between patient and the controls. Tumor stage, histopathological grade, tumor size/number and smoking condition were evaluated with IL-1RN, IL-4 and TNF-beta gene polymorphisms. Allele distribution frequencies of IL-1RN and IL-4 gene polymorphisms were significantly different between patients and control groups. However, allele distribution of TNF-beta gene was not statistically significant. There was no difference in allele distribution of the three genes in both groups regarding stage, tumor size, number of tumors and smoking condition. Although allele distribution of IL-4 gene showed significant difference considering histopathological grades in both smoking and total patients group, allele distribution of IL-1RN and TNF-beta was not different. The present research suggests that the IL-1RN and IL-4 gene polymorphisms are potential genetic markers of susceptibility to bladder cancer. In the future, clinical improvements on diagnosis, treatment and prognosis of bladder carcinoma are expected owing to development of more sensitive and specific tests for genetic polymorphisms of cytokines that are effective on inflammation.
Açıklama
[dc.description]
WOS: 000350369100014
Açıklama
[dc.description]
PubMed: 24850227
Kayıt Giriş Tarihi
[dc.date.accessioned]
2019-12-23
Açık Erişim Tarihi
[dc.date.available]
2019-12-23
Yayın Dili
[dc.language.iso]
eng
Konu Başlıkları
[dc.subject]
Bladder carcinoma
Konu Başlıkları
[dc.subject]
Gene polymorphisms
Konu Başlıkları
[dc.subject]
IL-1RN
Konu Başlıkları
[dc.subject]
IL-4
Konu Başlıkları
[dc.subject]
TNF-beta
Haklar
[dc.rights]
info:eu-repo/semantics/closedAccess
ISSN
[dc.identifier.issn]
0724-4983
ISSN
[dc.identifier.issn]
1433-8726
İlk Sayfa Sayısı
[dc.identifier.startpage]
389
Son Sayfa Sayısı
[dc.identifier.endpage]
395
Dergi Adı
[dc.relation.journal]
WORLD JOURNAL OF UROLOGY
Dergi Sayısı
[dc.identifier.issue]
3
Dergi Cilt Bilgisi
[dc.identifier.volume]
33
Tek Biçim Adres
[dc.identifier.uri]
https://dx.doi.org/10.1007/s00345-014-1323-4
Tek Biçim Adres
[dc.identifier.uri]
https://hdl.handle.net/20.500.12628/3597
Görüntülenme Sayısı ( Şehir )
Görüntülenme Sayısı ( Ülke )
Görüntülenme Sayısı ( Zaman Dağılımı )
Görüntülenme
441
09.12.2022 tarihinden bu yana
İndirme
1
09.12.2022 tarihinden bu yana
Son Erişim Tarihi
01 Ekim 2024 00:58
Google Kontrol
Tıklayınız
distribution IL-1RN TNF-beta polymorphisms allele bladder patients smoking between genetic frequencies condition different groups control clinical difference cancer histopathological carcinoma significant research present considering showed grades Although tumors suggests potential development inflammation effective cytokines specific
6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms